(SkyNewswire.com)---ROCKVILLE, Md.--Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has submitted a proposal in response to a request for proposal (RFP) issued by the U.S. Department of Health and Human Services (HHS) for a recombinant protective antigen anthrax vaccine (rPA). Emergents rPA vaccine candidate is a reformulated and more stable form of the rPA 102 vaccine originally developed at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and is well-positioned to be a leading candidate for an award under this RFP. One Phase II clinical trial of rPA 102 has been completed. HHSs RFP is designed to meet the governments stated goal to procure 25 million doses of an rPA anthrax vaccine for the Strategic National Stockpile (SNS). In the event that Emergent receives an award under the rPA RFP, doses of rPA procured by HHS would be in addition to the 18.75 million doses of the companys FDA-licensed product, BioThrax® (Anthrax Vaccine Adsorbed), that HHS is procuring under the existing $448M contract with Emergent. HHS has indicated that any awards under the rPA RFP would be granted at the end of 2008, at the earliest. ...
Anytime
(SkyNewswire.com)---ROCKVILLE, Md.--Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has submitted a proposal in response to a request for proposal (RFP) issued by the U.S. Department of Health and Human Services (HHS) for a recombinant protective antigen anthrax vaccine (rPA). Emergents rPA vaccine candidate is a reformulated and more stable form of the rPA 102 vaccine originally developed at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and is well-positioned to be a leading candidate for an award under this RFP. One Phase II clinical trial of rPA 102 has been completed. HHSs RFP is designed to meet the governments stated goal to procure 25 million doses of an rPA anthrax vaccine for the Strategic National Stockpile (SNS). In the event that Emergent receives an award under the rPA RFP, doses of rPA procured by HHS would be in addition to the 18.75 million doses of the companys FDA-licensed product, BioThrax® (Anthrax Vaccine Adsorbed), that HHS is procuring under the existing $448M contract with Emergent. HHS has indicated that any awards under the rPA RFP would be granted at the end of 2008, at the earliest. ...